11/18
08:07 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
Medium
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
11/18
05:33 am
cadl
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]
11/14
03:34 pm
cadl
Candel Therapeutics reports Q3 results [Seeking Alpha]
Low
Report
Candel Therapeutics reports Q3 results [Seeking Alpha]
11/14
08:12 am
cadl
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
Low
Report
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]
11/14
08:00 am
cadl
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Low
Report
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
11/7
08:00 am
cadl
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Medium
Report
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
11/5
09:00 am
cadl
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Medium
Report
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
10/28
08:00 am
cadl
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Low
Report
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
10/4
09:00 am
cadl
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Neutral
Report
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
9/13
10:49 am
cadl
Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30% [Yahoo! Finance]
Medium
Report
Candel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30% [Yahoo! Finance]
9/3
08:00 am
cadl
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference